Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) was down 0.9% on Friday . The company traded as low as $9.88 and last traded at $10.10, with a volume of 1,880,249 shares changing hands. The stock had previously closed at $10.19.

A number of equities research analysts recently weighed in on ARIA shares. Cowen and Company upgraded Ariad Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Thursday, May 5th. Barclays PLC increased their price target on Ariad Pharmaceuticals from $6.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, May 11th. Jefferies Group restated a “buy” rating and issued a $13.00 price target on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. William Blair restated a “buy” rating and issued a $10.00 price target on shares of Ariad Pharmaceuticals in a research note on Tuesday, May 24th. Finally, JMP Securities restated a “buy” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Ariad Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $9.19.

The company’s market cap is $1.95 billion. The stock has a 50 day moving average of $9.57 and a 200-day moving average of $7.66.

Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its earnings results on Thursday, July 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.70. The company had revenue of $65.30 million for the quarter, compared to analysts’ expectations of $60.64 million. The firm’s quarterly revenue was up 133.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) EPS. On average, equities research analysts anticipate that Ariad Pharmaceuticals Inc. will post ($0.09) earnings per share for the current year.

In other Ariad Pharmaceuticals news, SVP Hugh M. Cole sold 6,012 shares of the business’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $7.05, for a total value of $42,384.60. Following the transaction, the senior vice president now owns 29,262 shares of the company’s stock, valued at $206,297.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Athanese Lavidas sold 76,250 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $8.21, for a total value of $626,012.50. Following the completion of the transaction, the director now directly owns 141,631 shares in the company, valued at approximately $1,162,790.51. The disclosure for this sale can be found here.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.